Basecamp Research Appoints John Finn, Ph.D., as CSO, Expands Internationally with U.S. Lab and Offices, and Builds One of Europe's Largest Industrial Supercomputers with NVIDIA Accelerated Computing

Company Leadership and Expertise - John Finn, a globally-recognized leader in cell and gene therapy with over 25 years of experience, joins Basecamp Research as Chief Scientific Officer (CSO) [1][2] - Finn has a strong background in advancing gene and cell therapy through innovations in delivery and editing technologies, having held senior positions at Tome Biosciences, Codiak BioSciences, and Intellia Therapeutics [2] - Konstantinos Andrikopoulos, with 27 years of pharma IP experience, joins as Senior Vice President for Intellectual Property, further strengthening the company's leadership team [5] Expansion and Infrastructure - Basecamp Research establishes a new lab and office in Kendall Square, Cambridge, Mass., to expand its network of therapeutic partnerships and validate sophisticated biological systems [1][4] - The company has built one of the most advanced industrial compute infrastructures in Europe, featuring NVIDIA H200 GPUs, to support the training of long-context AI foundation models [7] - The company's proprietary foundational dataset has expanded rapidly, collecting 10 times more data in the last three months than in the previous three years, thanks to a $60 million Series B funding round [6] AI and Data-Driven Innovation - Basecamp Research is developing new classes of foundational AI models to tackle complex biological design challenges, leveraging its vast and unique dataset [6][7] - The company operates one of the world's largest commercial biodiscovery programs, spanning over 120 locations in more than 25 countries, to provide AI models with a comprehensive understanding of biology [8] - Basecamp Research collaborates with top institutions and pharmaceutical companies, including a multi-year partnership with Dr. David R. Liu at the Broad Institute of MIT and Harvard, to design novel protein sequences and biological systems [9] Industry Impact and Vision - Basecamp Research aims to advance programmable genetic medicines by combining its proprietary data and powerful AI models, addressing challenges in the field of life sciences [3][6] - The company's approach to exploring beyond known biology and leveraging AI to design complex biological systems has the potential to transform therapeutic research and development [10] - Basecamp Research has been recognized as one of Bloomberg's "Top 25 UK Startups to Watch" for 2024, highlighting its innovative contributions to the industry [10]